Θα πρέπει να αναζηηείηαι η παροσζία ζιωπηλής κολπικής μαρμαρσγή ζε αζθενείς με κρσπηογενές εγκεθαλικό επειζόδιο; Ποιά είναι η καλύηερη μέθοδος;

Similar documents
FORAME OVALE PERVIO E ICTUS CRIPTOGENETICO: Dimensione del problema. Roberto Mantovan, MD, PhD U.O. Cardiologia Ospedale M.

Subclinical AF: Implications of device based episodes

Thromboembolism During Sinus Rhythm in Patients with a History of Atrial Fibrillation

Atrial fibrillation: why it's important to make opportunities diagnosis in single chamber ICD patients

The Relationship Between Daily Atrial Tachyarrhythmia Burden From Implantable Device Diagnostics and Stroke Risk: The TRENDS Study

Implantable Cardiac Monitors for Atrial Fibrillation (AF) Detection: Ready for Routine Use?

ΑΣΥΜΠΤΩΜΑΤΙΚΗ ΚΟΛΠΙΚΗ ΜΑΡΜΑΡΥΓΗ

Στυλιανός Τζέης MD, PhD, FESC

Diagnosing atrial fibrillation using implantable devices

UTILITY OF THE IMPLANTABLE LOOP RECORDER

Defining Sub-Clinical Atrial Fibrillation and its management

ECG monitoring after ischemic stroke of TIA of unknown source with an insertable monitor? YES

Cryptogenic Stroke: What Don t We Know. Siddharth Sehgal, MD Medical Director, TMH Stroke Center Tallahassee Memorial Healthcare

Fibrillazione atriale : causa diretta marker di rischio di eventi cerebrovascolari non solo embolici?

Cryptogenic Stroke: The role of silent Atrial Fibrillation

Fibrillazione Atriale Fattore di Rischio o Marker di Stroke: Implicazioni Per La Terapia

Causal relationship between AF & stroke

Consensus document: Screening and Prevention of Atrial Fibrillation

2017 Cardiovascular Symposium CRYPTOGENIC STROKE: A CARDIOVASCULAR PERSPECTIVE DR. WILLIAM DIXON AND DR. VENKATA BAVAKATI SOUTHERN MEDICAL GROUP, P.A.

Atrial Fibrillation T. Jared Bunch, MD, FACC

SUBCLINICAL ATRIAL FIBRILLATION IN PATIENTS WITH IMPLANTABLE DEVICEs ORAL ANTICOAGULANT THERAPY: TO GIVE OR NOT TO GIVE, THIS IS THE PROBLEM!!

Atrial fibrillation (AF) has been the. Subclinical Atrial Fibrillation, Embolic Risk, and Anticoagulant Treatment

Device detected AF and atrial high rate episodes

Μηνύματα από τις σπουδαιότερες μελέτες στην ηλεκτροφυσιολογία το διάστημα

Post-ablation Management: Drug therapy, Anticoagulation and long-term Monitoring

Causal relationship between AF & stroke

Device Diagnostics and Stroke Prevention: State of the Art

Stroke Prevention in AF: How will it change in the next 5 years? Jeff Healey MD, MSc, FHRS Population Health Research Institute McMaster University

Rebuttal. Jerónimo Farré MD 2010

'Understanding Atrial Fibrillation: New Insights in Pathophysiology

What the general cardiologist should know about arrhythmia Stroke prevention in AF" Peter Ammann Kantonsspital St. Gallen

POWERFUL CARDIAC MONITORING

Speakers. 2015, American Heart Association 1

Index. cardiology.theclinics.com. Note: Page numbers of article titles are in boldface type.

Direct oral anticoagulants for Embolic Strokes of Undetermined Source? George Ntaios University of Thessaly, Larissa/Greece

Cryptogenic Strokes: Evaluation and Management

When does enhanced monitoring for atrial fibrillation add value?

Differences in the Slope of the QT-RR Relation Based on 24-Hour Holter ECG Recordings between Cardioembolic and Atherosclerotic Stroke

Should AF patients (after ablation) have anticoagulation forever? Can we ever stop it?

Continuous ECG telemonitoring with implantable devices: the expected clinical benefits

DEBATE: PFO MANAGEMENT TO CLOSE OR NOT TO CLOSE. Matthew Starr, MD Stroke Attending

Asymptomatic Atrial Fibrillation: Detection and Management. 18 December nd Annual Advances in Heart Disease Palace Hotel, San Francisco

Subclinical Atrial Fibrillation and the Risk of Stroke

Seek and Ye Shall Find: Surprising Findings When Using the ILR-LINQ

Spontaneous Atrial Fibrillation and Noacs and Reversal agents

ECTOPIC BEATS: HOW MANY COUNT?

TOP 3: EMBRACE. Lucy Vieira MD FRCP Neurologist MUHC. N Engl J Med Volume 370(26): June 26, David J.

True cryptogenic stroke

Management of Patients with Atrial Fibrillation Undergoing Coronary Artery Stenting 경북대의전원내과조용근

Cryptogenic Stroke and Underlying Atrial Fibrillation

Εμφύτευση απινιδωτών για πρωτογενή πρόληψη σε ασθενείς που δεν περιλαμβάνονται στις κλινικές μελέτες

Prof. Fiorenzo Gaita

Διαχείρηση Ασυμπτωματικού ασθενούς με ΗΚΓ τύπου Brugada

Does AF Ablation Lower Stroke Risk? Hugh Calkins MD Professor of Medicine Director of Electrophysiology Johns Hopkins Medical Institutions

EAE RECOMMENDATIONS FOR TRANSESOPHAGEAL ECHO. Cardiac Sources of Embolism. Luigi P. Badano, MD, FESC

Atrial fibrillation and advanced age

Supplementary webappendix

Cryptogenic Stroke: Finding Light in the Darkness

Can oral anticoagulants be stopped safely after a successful atrial fibrillation ablation?

Fibrillazione atriale: è sempre necessario ricercarla, e come?

REVEAL AF IN YOUR CRYPTOGENIC STROKE PATIENTS

Efstratios I. Charitos 1, Paul D. Ziegler 2, Ulrich Stierle 1, Hans-Hinrich Sievers 1, Hauke Paarmann 3, Thorsten Hanke 1. What s New?

Management of Anticoagulation during Device Implants; Coumadin to Novel Agents

Make the Connection A clinical compendium on the relationship between AF, stroke, and early intervention

How Can We Properly Manage Patients With Stroke of Undetermined Origin?

Results from RE-LY and RELY-ABLE

Følgende dias er fremlagt ved DCS / DTS Fællesmøde 13. januar 2011 og alle rettigheder tilhører foredragsholderen. Gengivelse må kun foretages ved

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

Antithrombotic Summit Basel 2012 Basel, 26. April Peter T. Buser Klinik Kardiologie Unviersitätsspital Basel

OAC after apparently successfull AF ablation: when, why, and how?

SUPPLEMENTARY INFORMATION

Non-commercial use only

CRYPTOGENIC STROKE THERAPY AWARENESS PRESENTATION. Reveal LINQ TM

IS THERE A LINK BETWEEN ATRIAL FIBRILLATION AND MY STROKE? Finding answers about cryptogenic stroke

Antithrombotic. DAPT or OAC?

» A new drug s trial

Embolic Stroke of Undetermined Source (ESUS) Lee Birnbaum, MD, MS Depts of Neurology and Neurosurgery UTHSCSA

Patent Foramen Ovale: Diagnosis and Treatment

Primary Care Atrial Fibrillation Update: Anticoagulation and Left Atrial Appendage Occlusion. Greg Francisco, MD, FACC

Is Stroke a Paradoxical Embolism in Patients with Patent Foramen Ovale?

Fibrillazione atriale subclinica e rischio di ictus ischemico

I, (Issam Moussa) DO NOT have a financial interest/arrangement t/ t or affiliation with one or more organizations that could be perceived as a real

Management of ATRIAL FIBRILLATION. in general practice. 22 BPJ Issue 39

CPAG Summary Report for Clinical Panel Patent Foramen Ovale Closure for Secondary Prevention of Cryptogenic Stroke

MODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC

Stroke and ASA / FO REBUTTAL

Patient Presentation

NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE SCOPE. Clinical guideline for the management of atrial fibrillation

Controversies in Risk Stratification

Left Atrial Appendage Closure for Atrial Fibrillation 2015 UPDATE

Role of cardiac imaging for catheterbased left atrial appendage closure

Risk Stratification for Stroke Prevention in Patients with Atrial Fibrillation: The emerging role of biomarkers

Atrial Fibrillation and Common Supraventricular Tachycardias. Sunil Kapur MD

CARDIOLOGY. Certification Updates with Clinical Aspects. Federal Aviation Administration

Identifying Patients for Anticoagulation: While Many Patients Remain Untreated, Who Should NOT be Anticoagulated?

Cryptogenic Stroke/PFO with Thrombophilia and VTE: Do We Know What To Do?

Secondary Stroke Prevention: A Precautionary Tale

CRYPTOGENIC STROKE. Reveal LINQ TM THERAPY AWARENESS PRESENTATION

Χρήση έξυπνων τεχνολογιών στην ανίχνευση κολπικής μαρμαρυγής Use of smart technology in atrial fibrillation detection

Atrial fibrillation and stroke. Isabelle C Van Gelder University Medical Center Groningen The Netherlands

Transcription:

Θα πρέπει να αναζηηείηαι η παροσζία ζιωπηλής κολπικής μαρμαρσγή ζε αζθενείς με κρσπηογενές εγκεθαλικό επειζόδιο; Ποιά είναι η καλύηερη μέθοδος; Νικόλαος Φραγκάκης Λέκηορας Καρδιολογίας, FESC Ιπποκράηειο Νοζοκομείο Θεζζαλονίκης

Cryptogenic Stroke (CS) Definition Brain infarction that is not attributable to a source of definite cardioembolism, large artery atherosclerosis, or small artery disease despite extensive vascular, cardiac, and serologic evaluation ie: stroke with no identifiable cause CS is a diagnosis of exclusion Adams HP, et al. Stroke 1993;24:35-41

tests that must be performed before considering a stroke cryptogenic Magnetic resonance imaging (MRI) or computed tomography (CT) 12-lead ECG 24-hour ECG monitoring (eg, Holter) Transesophageal echocardiography Computed tomography angiography (CTA), magnetic resonance angiography (MRA), or conventional angiography of head and neck Evaluation for prothrombotic states in patients < 55 years old CRYSTAL AF study

Stroke Subtypes

Cryptogenic Stroke Suspected Thromboembolic sources Atrial Fibrillation Atrial Septal Aneurysm Patent Foramen Ovale Peripheral Artery Disease

Atrial Fibrillation (cryptogenic?) Asymptomatic AF in up to 30% of pts > 65 yrs Poor correlation between symptoms and AF episodes Stroke is first manifestation in 25% of AF associated stroke In pts with AF- associated stroke, AF is paroxysmal in 30-35% of patients Asymptomatic AF > symptomatic AF

Risk of Stroke in Paroxysmal vs Sustained AF The ACTIVE W trial Similar risk for thromboembolic events in paroxysmal versus sustained AF in patients under treatment. S. Hohnloser. J Am Coll Cardiol 2007; 50: 2156 61

is it important to ascertain the diagnosis of AF after an ischemic stroke (?)

CHADS 2 criteria Score Congestive heart failure 1 Hypertension 1 Age >75 yrs 1 Diabetes mellitus 1 Stroke/transient ischaemic attack 2

Survival after Stroke Inappropriate decisions concerning the therapy (anticoagulation) Kolominsky-Rabas PL et al. Stroke 2001

Detection of AF The More You Look, The More You Find Jabaudon D, et al. Stroke 2004

Prolonged Holter ECG The More You Look, The More You Find

Enrollment ASSERT Study Design Pts with indication to Dual- Chamber Pacing SSS, >65 yrs, Hypertension, without history of AF and no OAC First Monitoring Phase (3 months after 1 month for lead maturation) Classification of patients with AF (AF>6min) and without AF (AF<6 min) FU and Collection of Embolic Events AF Pts FU=2.5 years No-AF Pts FU and Collection of Embolic Events JS Healey et al. N Engl J Med 2012

ASSERT Study 2582 patients, 76±7 years, 42% female, mean CHADS 2 score 2.41 2.5 in the risk of ischemic stroke At 3 months, 10% of pts had 1 AF episode > 6 minutes During the follow-up period, subclinical AT/AF 34.5% N Engl J Med 2012

ASSERT Study Risk of ischemic stroke

Is there a cut-off episode duration discriminating between clinically relevant and nonrelevant episode of AF?

AF and TE Events 725 patients with an MDT AT500 pacemaker followed 2-years for arterial embolic events More events in pts. with AF episodes >24 hours: >3-fold increase A. Capucci. J Am Coll Cardiol 2005;46:1913-1920

Circ Arrhythm Electrophysiol 2009

TRENDS: Results Circ Arrhythm Electrophysiol 2009

TRENDS: Conclusions AT/AF burden > 5.5 hours on any day in the most recent 30 days is associated with an approximate doubling of the risk of TE compared with zero AT/AF burden, after controlling for clinical stroke risk factors and antithrombotic use AT/AF burden detected by implanted devices may be a TE risk factor that is independent of standard clinical stroke risk factors Circ Arrhythm Electrophysiol 2009

Europace 2012

Borriani G, et al. Stroke 2011

data of daily AF burden can improve risk stratification for stroke Borriani G, et al. Stroke 2011

Kaufman ES, et al. Heart Rhythm 2012;9:1241 1246

Evolution in the Technology of Continuous Atrial Fibrillation Monitoring

Currently Available Implantable Cardiac Monitors

AF algorithm of Subcutaneous electrocardiographic monitors Lorenz Plot is a graphic representation of the beat-to-beat variations of the cardiac cycles

Example of a Patient Being Followed by an Implantable Cardiac Monitor

Parameter % Sensitivity 96.1 Specificity 85.4 Positive predictive value 79.3 Negative predictive value 97.4 Hindricks G et al. Circ Arrhythm Electrophysiol 2010

JACC 2011

Cryptogenic Stroke and underlying Atrial Fibrillation (CRYSTAL AF): Design and rationale Anil-Martin Sinha, MD, DPhil, Hans-Christoph Diener, MD, PhD, Carlos A. Morillo, MD, Tommaso Sanna, MD, Richard A. Bernstein, MD, PhD, Vincenzo Di Lazzaro, MD, Rod Passman, MD, Frank Beckers, PhD and Johannes Brachmann, MD, PhD American Heart Journal Volume 160, Issue 1, Pages 36-41.e1 (July 2010) DOI: 10.1016/j.ahj.2010.03.032 CRYSTAL AF trial seeks to determine the incidence of paroxysmal AF in patients with cryptogenic stroke and TIA using a long-term implantable monitor Source: American Heart Journal 2010; 160:36-41

research questions Is there a threshold of AF in patients with CS below which OAC is not needed? what that threshold is? whether the presence of other risk factors influences the threshold? whether the overall burden of AF, the length of individual episodes, the frequency with which it occurs, is most important?

Conclusions Patients with stroke often suffer from cardioembolic events. Some of them remain cryptogenic In the latter, AF is suspected as the main source of stroke/ TIA Detection of AF remains challenging, with ECG detection rate ~5%, Holter ~ 10% & 7 days Holter ~ 15% Implantable devices are validated tools for measuring AF burden AF burden may be a clinically relevant parameter for improving risk stratification for stroke

Ευχαριστώ για την προσοχή σας